Substantial doubt about the company's ability to continue as a going concern.
“After considering these plans and the guidance within ASC 205-40, we concluded that substantial doubt about our ability to continue as a going concern had not been alleviated for the one-year period following the issuance of these condensed consolidated financial statements. Our expected future operating losses and negative cash flows, together with our need for additional funding to support planned operations, raise substantial doubt about our ability to continue as a going concern for a period of one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 9, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Coherus Oncology, Inc. is prioritizing esophageal cancer, cutting headcount approximately 30% from about 140 to 100 FTEs and expecting $6 to $7 million per quarter in savings; cash runway remains less than 12 months.
Coherus Oncology reported $83.6 million in cash and marketable securities as of September 30, 2026. Management concluded substantial doubt about the company's ability to continue as a going concern remained, citing expected operating losses, negative cash flows and additional funding needs.
Coherus Oncology prioritized tagmokitug/toripalimab development for esophageal cancer, reduced headcount by ~30%, and reported Q3 2026 LOQTORZI net revenue of $14.0 million. Q3 net loss from continuing operations was $38.9 million, or $(0.25) per diluted share.
On October 28, 2026, Coherus Oncology reported tagmokitug plus toripalimab and chemotherapy achieved 75% confirmed overall response rate in first-line ESCC, rising to 89% after the data cutoff; enrollment expansion is planned.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Coherus Oncology reported Q2 2026 LOQTORZI net revenue of $13.6M (up 15% sequentially) with rebounded demand and the highest new patient starts since launch, while reiterating full-year LOQTORZI revenue guidance of $57–$62M; clinical enrollment completed in HNSCC, CRC and HCC studies with emerging tagmokitug activity expected to be disclosed in October; however, $37.5M Udenica earnout milestones were not achieved in Q2 and net loss from continuing operations was $33.3M with cash declining to $105.3M.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CHRS
this stock
Coherus Oncology, Inc.
|
$81.21M | -63.0% | -100.0% | — | 8.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Coherus Oncology reported $83.6 million in cash and marketable securities as of September 30, 2026. Management concluded substantial doubt about the company's ability to continue as a going concern remained, citing expected operating losses, negative cash flows and additional funding needs.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CHRS | -31.8% | -46.9% | -68.0% | -36.7% | -63.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -34.3% | -45.8% | -68.5% | -36.5% | -73.6% |
